|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Conatus Pharmaceuticals Inc.
| | | Phone: | (858) 457-7224 | Fax: | (858) 558-8920 | Year Established: | 2005 | Ticker: | CNAT | Exchange: | NASDAQ | Main Contact: | Daniel L. Ripley, Senior VP, Business Development, Program and Alliance Management | | Other Contacts: | Keith W. Marshall, Executive VP, COO & CFO Edward F. Smith III, Ph.D., Senior VP, RA & QA Mark F. Morris, Head of Biostatistics Gary Craig Burgess, M.B., Ch.B. Mmed, Senior VP & CMO Alfred P. Spada, Ph.D., Senior VP, R&D & Co-Founder Charles J. Cashion, Senior VP & Co-Founder Steven J. Mento, Ph.D., President, CEO & Co-Founder
| | Company Description | Conatus Pharmaceuticals is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus’ lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. Conatus acquired the Idun subsidiary from Pfizer in 2010. | |
|
|
|
|
|